2648504-55-4
2648504-55-4
Chemical Structure
Tulisokibart
Synonym(s): PRA023; MK-7240
- CAS No.: 2648504-55-4
- Formula:N/A
- Molecular Weight:(143.96 kDa)
SMILES: [Tulisokibart]
Biological Activity: Tulisokibart (PRA023) is a humanized IgG1-κ monoclonal antibody. Tulisokibart targets to TNFSF15/TL1A. Tulisokibart can be used to study a variety of inflammatory/fibrotic diseases, such as Crohn's Disease (CD) and ulcerative colitis[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Tulisokibart | 98.69% | Tulisokibart (PRA023) is a humanized IgG1-κ monoclonal antibody. Tulisokibart targets to TNFSF15/TL1A. Tulisokibart can be used to study a variety of inflammatory/fibrotic diseases, such as Crohn's Disease (CD) and ulcerative colitis. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Feagan B G, Sands B, Siegel C A, et al. DOP87 The Anti-TL1A Antibody PRA023 Demonstrated Proof-of-Concept in Crohn’s Disease: Phase 2a APOLLO-CD Study Results[J]. Journal of Crohn's and Colitis, 2023, 17(Supplement_1): i162-i164.
- [2]. B Sands, et al. OP40 PRA023 Demonstrated Efficacy and Favorable Safety as Induction Therapy for Moderately to Severely Active UC: Phase 2 ARTEMIS-UC Study Results, Journal of Crohn's and Colitis, Volume 17, Issue Supplement_1, February 2023, Pages i56–i59
Keywords
